Showing 1921-1930 of 2050 results for "".
- Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-selects-agc-biologics-as-lead-manufacturer-of-tthx1114-for-treatment-of-corneal-diseases/2477274/AGC Biologics, a global Contract Development and Manufacturing Organization for Biopharmaceuticals, and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound, TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore
- Bausch Health and Clearside Biomedical Announce Publication of Pivotal Phase 3 Data on Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-publication-of-pivotal-phase-3-data-on-xipere/2477264/Bausch Health Companies and Clearside Biomedical announced that results from the randomized, controlled, double-masked phase 3 clinical trial (PEACHTREE study) of Xipere (triamcinolone acetonide suprachoroidal injectable suspension), have been published in Ophthalmology.1 Xiper
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- Tangible Science Announces Timing for Tangible Boost Launchhttps://modernod.com/news/tangible-science-announces-timing-for-tangible-boost-launch/2477250/Tangible Science recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible Boost. In 2019, the company developed agreements and collaborated with SynergEyes, Contamac, Bausch+Lomb, Paragon Vision Sciences, and Acuity Polymers to
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati
- Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint-in-phase-2-mystic-trial-in-subjects-with-dry-eye-disease/2477225/Oyster Point Pharma announced positive topline results from its phase 2 MYSTIC study in dry eye disease. Results showed a statistically significant improvement in Schirmer’s score from baseline at Day 84 in both doses as compared to control.
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- CRST: 2019 Year in Focushttps://modernod.com/news/2019-year-in-focus/2477197/Fueled by an influx of investment capital in recent years and a streamlined regulatory review process, the number of ophthalmic products approved or introduced in 2019 continued to rise steadily throughout the year. According to recent figures from pharmaceutical market research company Strategic
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th
- CooperVision Earns Global Impact Award for Rebate Donation Program Resulting in $800,000 Raised for Optometry Giving Sighthttps://modernod.com/news/coopervision-earns-global-impact-award-for-rebate-donation-program-resulting-in-800000-raised-for-optometry-giving-sight/2477119/CooperVision offers a contact lens rebate donation program that enables consumers to designate all or part of their rebates to be given to Optometry Giving Sight (OGS). Seven years after the launch of that program, CooperVision has been recognized by 360insights, the company’s rebate and incentiv